Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

CNTA

Centessa Pharmaceuticals plc ADR

Sep 20 • 04:00PM ET

16.58

Dollar change +0.73
Percentage change 4.61	%

Healthcare • Biotechnology • United Kingdom • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IBB GWX BBC BIB IBBQ FPXE

Index	-	P/E	-	EPS (ttm)	-1.56	Insider Own	33.28%	Shs Outstand	98.77M	Perf Week	-2.41%
Market Cap	1.88B	Forward P/E	-	EPS next Y	-1.70	Insider Trans	-1.11%	Shs Float	75.51M	Perf Month	35.79%
Income	-157.47M	PEG	-	EPS next Q	-0.40	Inst Own	43.30%	Short Float	2.61%	Perf Quarter	82.20%
Sales	6.91M	P/S	271.57	EPS this Y	-0.72%	Inst Trans	0.05%	Short Ratio	3.77	Perf Half Y	37.25%
Book/sh	2.54	P/B	6.54	EPS next Y	-7.35%	ROA	-39.78%	Short Interest	1.97M	Perf Year	167.85%
Cash/sh	2.60	P/C	6.36	EPS next 5Y	-	ROE	-55.88%	52W Range	5.15 - 17.59	Perf YTD	108.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-42.32%	52W High	-5.74%	Beta	1.45
Dividend TTM	-	Quick Ratio	13.29	Sales past 5Y	0.00%	Gross Margin	86.10%	52W Low	221.94%	ATR (14)	1.22
Dividend Ex-Date	-	Current Ratio	13.29	EPS Y/Y TTM	14.73%	Oper. Margin	-2250.36%	RSI (14)	66.61	Volatility	6.50% 8.49%
Employees	76	Debt/Eq	0.30	Sales Y/Y TTM	-	Profit Margin	-2278.02%	Recom	1.00	Target Price	26.14
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	-52.67%	Payout	-	Rel Volume	2.73	Prev Close	15.85
Sales Surprise	-	EPS Surprise	-3.33%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	523.83K	Price	16.58
SMA20	14.67%	SMA50	35.91%	SMA200	66.98%	Trades		Volume	1,429,917	Change	4.61%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$11 → $26
Sep-19-24	Initiated	B. Riley Securities	Buy	$33
Jul-18-24	Initiated	Oppenheimer	Outperform	$14
Nov-15-23	Upgrade	Jefferies	Hold → Buy	$4 → $11
Oct-26-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$4 → $8
Jun-21-23	Initiated	Evercore ISI	Outperform
Jun-12-23	Initiated	Guggenheim	Buy	$9
Mar-17-23	Initiated	SVB Securities	Outperform	$6
Aug-12-22	Downgrade	Morgan Stanley	Overweight → Underweight	$10 → $5
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$19
Jun-03-22	Downgrade	Jefferies	Buy → Hold	$37 → $4
Feb-11-22	Initiated	Goldman	Neutral	$12

Show Previous Ratings

Sep-12-24 10:34PM	Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares (GlobeNewswire) +9.82% +12.52%
Sep-11-24 04:04PM	Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares (GlobeNewswire) -5.69%
Sep-10-24 04:34PM	Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
12:19PM	Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers (Benzinga)
11:18AM	Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
08:15AM	Loading…
08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
07:00AM	Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers (GlobeNewswire)
Aug-27-24 08:00AM	Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Aug-24-24 01:18AM	Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ... (GuruFocus.com)
Aug-21-24 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade (Zacks)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-10-24 07:00AM	Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer (GlobeNewswire)
May-28-24 09:35AM	Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA) (Zacks)
08:45AM	Loading…
May-21-24 08:45AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-13-24 09:54PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 (GlobeNewswire)
Apr-24-24 04:47AM	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS (MT Newswires)
Apr-23-24 09:36PM	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire) -6.00%
06:00PM	Centessa Pharmaceuticals Eyes $100 Million in ADS Offering (MT Newswires)
04:17PM	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Apr-22-24 07:00AM	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire) -5.39%
Mar-28-24 11:53PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
06:11PM	Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results (GuruFocus.com)
04:28PM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
Mar-27-24 01:26AM	Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares (GuruFocus.com)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace) +5.18%
Feb-22-24 08:00AM	Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 07:00AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire) +24.13%
08:00AM	Loading…
Jan-22-24 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-13-23 08:00AM	Centessa Pharmaceuticals to Present at the 42 Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-23 12:05PM	Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia (GlobeNewswire)
Dec-05-23 09:55AM	Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire) -7.69%
Nov-16-23 09:55AM	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) +6.25% +8.75%
Nov-13-23 04:05PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 (GlobeNewswire)
Nov-02-23 09:09AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors (GlobeNewswire)
Oct-30-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.32%
Oct-25-23 08:00AM	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders (GlobeNewswire) -6.02%
Oct-03-23 08:00AM	Centessa Pharmaceuticals Announces Additions to Senior Leadership Team (GlobeNewswire)
Sep-04-23 10:51AM	Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why (Zacks)
Aug-31-23 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire) +6.35%
Aug-23-23 05:08PM	Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress (GlobeNewswire)
Aug-14-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 (GlobeNewswire)
Jul-10-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors (GlobeNewswire) +5.04%
May-24-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-22-23 07:00AM	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B (GlobeNewswire)
May-12-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 (GlobeNewswire)
Apr-27-23 12:07PM	Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22% (Simply Wall St.) -5.71%
Mar-30-23 07:00AM	Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire)
Mar-27-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director (PR Newswire) +5.04%
08:32AM	Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings? (Zacks)
Mar-01-23 08:00AM	Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines (GlobeNewswire)
Feb-06-23 08:00AM	Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)
Feb-02-23 08:00AM	Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-26-23 09:08AM	Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors (GlobeNewswire)
Dec-10-22 03:30PM	Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia (GlobeNewswire)
Nov-30-22 08:00AM	Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson (GlobeNewswire)
Nov-18-22 10:29AM	While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership (Simply Wall St.)
Nov-10-22 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022 (GlobeNewswire)
Nov-03-22 09:04AM	Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-20-22 08:33AM	Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022) (GlobeNewswire)
Sep-14-22 09:00AM	Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B (GlobeNewswire) +8.92%
Sep-12-22 07:00AM	Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index (GlobeNewswire)
Aug-29-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-22 08:37AM	Centessa Culls Early-Stage Asset For Inherited Disorder (Benzinga) -5.19%
06:30AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874 (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
Jul-25-22 08:00AM	Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs (GlobeNewswire)
Jul-01-22 08:40AM	Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors (GlobeNewswire) +6.16%
Jun-23-22 09:55AM	Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Jun-17-22 02:35PM	BMO Capital Sees Almost 300% Upside On Centessa Stock (Benzinga) +19.08%
Jun-11-22 10:06AM	What Kind Of Investors Own Most Of Centessa Pharmaceuticals plc (NASDAQ:CNTA)? (Simply Wall St.)
Jun-06-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-05-22 07:00AM	Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting (GlobeNewswire)
Jun-03-22 08:29AM	Record-Setting Biotech Plunges 25% After Axing Lead Program (TheStreet.com)
Jun-02-22 06:29AM	Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire) -27.78%
May-16-22 07:00AM	Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-30-22 04:01PM	Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-22 04:30PM	Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day (GlobeNewswire)
Mar-07-22 07:30AM	Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise (GlobeNewswire)
Feb-24-22 07:30AM	Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire)
Feb-17-22 02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Jan-01-22 07:33AM	Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares? (Simply Wall St.)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +10.06%
Dec-14-21 07:30AM	Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application (GlobeNewswire) -9.39%
Dec-13-21 04:15PM	Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-06-21 05:00PM	2 Big Stock Bets That Are Insiders Are Buying Now (InvestorPlace) -5.58% +9.08%
Nov-24-21 06:59AM	Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Nov-15-21 07:00AM	Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-10-21 04:45PM	Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021 (GlobeNewswire)
Nov-01-21 07:29PM	Why Did Centessa's Shares Plunge 10% Today? (Benzinga) -18.55% -6.78%
10:35AM	Mid-Morning Market Update: Markets Mixed; PG&E Earnings Miss views (Benzinga)
07:30AM	Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874 (GlobeNewswire)
Oct-18-21 08:00AM	Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists (Business Wire)

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHA SAURABH	Chief Executive Officer	Sep 20 '24	Sale	16.53	55,000	908,985	721,924	Sep 20 04:55 PM
SAHA SAURABH	Officer	Sep 20 '24	Proposed Sale	16.45	55,000	904,750		Sep 20 04:01 PM
Weinhoff Gregory M	Chief Business Officer	Sep 10 '24	Option Exercise	5.84	30,000	175,200	253,369	Sep 12 08:01 PM
Weinhoff Gregory M	Chief Business Officer	Sep 10 '24	Sale	17.00	30,000	510,000	223,369	Sep 12 08:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 10 '24	Option Exercise	5.84	175,000	1,022,000	951,924	Sep 12 08:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 10 '24	Sale	16.52	175,000	2,891,822	776,924	Sep 12 08:01 PM
SAHA SAURABH	Officer	Sep 10 '24	Proposed Sale	16.52	175,000	2,891,822		Sep 10 04:06 PM
Weinhoff Gregory M	Officer	Sep 10 '24	Proposed Sale	17.00	30,000	510,000		Sep 10 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Sep 09 '24	Option Exercise	5.84	25,000	146,000	248,369	Sep 09 05:06 PM
Weinhoff Gregory M	Chief Business Officer	Sep 09 '24	Sale	15.00	25,000	375,000	223,369	Sep 09 05:06 PM
Weinhoff Gregory M	Officer	Sep 09 '24	Proposed Sale	15.00	25,000	375,000		Sep 09 04:07 PM
SAHA SAURABH	Chief Executive Officer	Aug 23 '24	Sale	12.30	46,651	573,905	776,924	Aug 23 05:13 PM
Weinhoff Gregory M	Chief Business Officer	Aug 23 '24	Sale	12.29	17,802	218,792	223,369	Aug 23 05:12 PM
Weinhoff Gregory M	Chief Business Officer	Aug 22 '24	Sale	12.17	12,198	148,430	241,171	Aug 23 05:12 PM
Weinhoff Gregory M	Officer	Aug 23 '24	Proposed Sale	12.29	17,802	218,792		Aug 23 04:19 PM
SAHA SAURABH	Officer	Aug 23 '24	Proposed Sale	12.30	46,651	573,905		Aug 23 04:13 PM
SAHA SAURABH	Chief Executive Officer	Aug 20 '24	Sale	12.32	4,169	51,368	827,755	Aug 22 05:15 PM
SAHA SAURABH	Chief Executive Officer	Aug 21 '24	Sale	12.25	3,674	44,989	824,081	Aug 22 05:15 PM
SAHA SAURABH	Chief Executive Officer	Aug 22 '24	Sale	12.23	506	6,188	823,575	Aug 22 05:15 PM
Weinhoff Gregory M	Officer	Aug 22 '24	Proposed Sale	12.24	12,198	149,304		Aug 22 04:32 PM
SAHA SAURABH	Officer	Aug 22 '24	Proposed Sale	12.23	506	6,188		Aug 22 04:13 PM
SAHA SAURABH	Officer	Aug 21 '24	Proposed Sale	12.25	3,674	44,989		Aug 21 04:38 PM
SAHA SAURABH	Officer	Aug 20 '24	Proposed Sale	12.32	4,169	51,368		Aug 20 04:52 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Option Exercise	3.94	45,000	177,252	122,685	Mar 26 04:16 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Sale	11.88	51,160	607,960	71,525	Mar 26 04:16 PM
Rotman Harris	SVP Regulatory Affairs	Feb 01 '24	Sale	8.10	4,267	34,574	62,625	Feb 02 05:03 PM

Open in Screener

CLVT

Clarivate Plc

Sep 20 • 04:00PM ET

6.94

Dollar change -0.03
Percentage change -0.43	%

Technology • Information Technology Services • United Kingdom • NYSE

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF SCHA DFAT SCHM IWR DFAS AVUV IWD DFAC IYW

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	41.39%	Shs Outstand	666.10M	Perf Week	5.63%
Market Cap	5.03B	Forward P/E	8.76	EPS next Y	0.79	Insider Trans	0.09%	Shs Float	424.40M	Perf Month	5.95%
Income	-1280.20M	PEG	-	EPS next Q	0.19	Inst Own	61.56%	Short Float	6.23%	Perf Quarter	24.82%
Sales	2.60B	P/S	1.93	EPS this Y	-9.30%	Inst Trans	-4.58%	Short Ratio	6.19	Perf Half Y	-5.58%
Book/sh	7.74	P/B	0.90	EPS next Y	6.55%	ROA	-9.39%	Short Interest	26.46M	Perf Year	-5.32%
Cash/sh	0.52	P/C	13.35	EPS next 5Y	1.30%	ROE	-19.31%	52W Range	4.97 - 9.60	Perf YTD	-25.05%
Dividend Est.	-	P/FCF	13.21	EPS past 5Y	60.20%	ROI	-12.44%	52W High	-27.75%	Beta	1.17
Dividend TTM	-	Quick Ratio	0.90	Sales past 5Y	23.91%	Gross Margin	38.33%	52W Low	39.64%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	0.90	EPS Y/Y TTM	69.70%	Oper. Margin	10.30%	RSI (14)	61.21	Volatility	3.27% 3.45%
Employees	12000	Debt/Eq	0.84	Sales Y/Y TTM	-0.25%	Profit Margin	-49.19%	Recom	2.00	Target Price	7.70
Option/Short	Yes / Yes	LT Debt/Eq	0.84	EPS Q/Q	-120.47%	Payout	-	Rel Volume	1.14	Prev Close	6.97
Sales Surprise	-0.25%	EPS Surprise	10.38%	Sales Q/Q	-2.77%	Earnings	Aug 06 BMO	Avg Volume	4.27M	Price	6.94
SMA20	4.34%	SMA50	8.09%	SMA200	-3.27%	Trades		Volume	4,865,009	Change	-0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-23	Downgrade	Wells Fargo	Equal Weight → Underweight	$8
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$10 → $8.50
Sep-08-23	Downgrade	Barclays	Equal Weight → Underweight	$8 → $7
Aug-25-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$9 → $8
Aug-07-23	Downgrade	BofA Securities	Neutral → Underperform	$10 → $6
Aug-04-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$15 → $8
Jun-13-23	Initiated	Oppenheimer	Outperform	$11
Mar-15-23	Resumed	BofA Securities	Neutral
Feb-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$11 → $12
Jul-13-22	Initiated	Wells Fargo	Overweight	$20
Feb-04-22	Downgrade	Citigroup	Buy → Neutral	$35 → $16
Feb-03-22	Downgrade	Barclays	Overweight → Equal Weight	$16
Dec-21-21	Resumed	Citigroup	Buy	$35
Dec-13-21	Resumed	Goldman	Buy	$30
Aug-16-21	Initiated	BofA Securities	Buy	$28
Aug-04-21	Resumed	RBC Capital Mkts	Outperform	$29
Mar-31-21	Initiated	Jefferies	Buy	$30
Mar-11-21	Resumed	Citigroup	Buy	$36
Mar-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$28

Show Previous Ratings

Sep-19-24 06:30PM	Analyst Report: Clarivate Plc (Morningstar Research)
03:00AM	Clarivate Reveals Citation Laureates 2024 (PR Newswire)
Sep-18-24 03:00AM	Clarivate Launches Generative AI-Powered Primo Research Assistant (PR Newswire)
03:00AM	Clarivate Announces 15th Annual Pharmavision India Conference Agenda (PR Newswire)
Sep-14-24 11:23AM	Goldman Thinks Clarivate Plc (CLVT) Is A Long-Term AI Stock Set To Rally Eventually (Insider Monkey)
03:00AM	Loading…
Sep-09-24 03:00AM	Clarivate Report Unveils the Transformative Role of Artificial Intelligence on Shaping the Future of the Library (PR Newswire)
Sep-05-24 09:00AM	Clarivate to Present at the Goldman Sachs Communacopia + Technology Conference on September 12 (PR Newswire)
Sep-04-24 03:00AM	Clarivate Launches Generative AI-Powered Web of Science Research Assistant (PR Newswire)
Aug-20-24 03:00AM	Clarivate Names Melanie Margolin as Chief Administrative and Legal Officer (PR Newswire)
Aug-07-24 08:15AM	Clarivate to Present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference on August 12 (PR Newswire) -5.93%
Aug-06-24 12:33PM	Analyst Report: Clarivate Plc (Morningstar Research) -12.20%
06:01AM	Clarivate Appoints Former ProQuest CEO Matti Shem Tov as the Company's Next CEO (PR Newswire)
06:00AM	Clarivate Reports Second Quarter 2024 Results (PR Newswire)
Aug-05-24 06:40PM	Analyst Report: Clarivate Plc (Morningstar Research)
Jul-30-24 03:00AM	Clarivate Introduces New OFF-X Platform for Preclinical and Clinical Safety Intelligence (PR Newswire)
06:30PM	Loading…
Jul-25-24 06:30PM	Analyst Report: Clarivate Plc (Morningstar Research)
Jul-24-24 07:30AM	Clarivate Director Richard Roedel to Retire from Board of Directors (PR Newswire)
Jul-22-24 06:00AM	Clarivate Acquires Rowan TELS to Enhance Support for Patent Practitioners (PR Newswire)
Jul-18-24 03:00AM	Clarivate to Partner with OhioLINK and SearchOhio to Create a New Unified Library Experience Across the State of Ohio (PR Newswire)
03:00AM	BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards (PR Newswire)
Jul-16-24 09:00AM	Clarivate to Report Second Quarter 2024 Results on August 6, 2024 (PR Newswire) +6.04%
03:00AM	Clarivate Annual G20 Scorecard Examines Global Research and Innovation Trends Across G20 Members (PR Newswire)
Jul-11-24 05:34AM	Should You Consider Adding Clarivate Plc (CLVT) to Your Portfolio? (Insider Monkey)
03:40AM	Should You Invest in Red Violet (RDVT)? (Insider Monkey)
Jul-10-24 04:00AM	Clarivate Reveals First Year of Unitary Patent Court Litigation Activity (PR Newswire)
Jul-02-24 03:00AM	Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities (PR Newswire)
Jun-27-24 06:15AM	Clarivate Report Demonstrates Societal Impact of Digital Health Research and Innovation Growth (PR Newswire)
Jun-25-24 11:51PM	Clarivate Plc (CLVT): The Best AI Stock to Buy Under $10? (Insider Monkey)
Jun-24-24 03:00AM	Clarivate Launches IP Collaboration Hub (PR Newswire)
Jun-20-24 03:00AM	Clarivate Reveals World's Leading and Trusted Journals with the 2024 Journal Citation Reports (PR Newswire)
03:00AM	Loading…
Jun-19-24 03:00AM	Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report (PR Newswire)
Jun-08-24 10:08PM	Top 50 Companies in London (Insider Monkey)
Jun-04-24 03:00AM	Clarivate Launches Research Horizon Navigator to Pinpoint Future Breakthrough Areas (PR Newswire)
May-31-24 03:00AM	Clarivate Expands Real-World Data Offering with Addition of Social Determinant of Health (SDoH) Attributes from HealthWise Data (PR Newswire)
May-30-24 05:15PM	Clarivate Announces Conversion Date and Conversion Rate for Series A Mandatory Convertible Preferred Shares (PR Newswire)
03:00AM	Clarivate Celebrates 500 Institutions Adopting Rialto Marketplace Solution (PR Newswire)
May-29-24 09:15AM	Clarivate to Present at Upcoming Investor Conferences in June 2024 (PR Newswire)
May-22-24 03:00AM	Clarivate Identifies Five Breakthrough Medical Technologies Set to Transform Patient Care in 2024 (PR Newswire)
May-21-24 03:00AM	New Clarivate Report Indicates Solid Growth in 2024 Global Trademark Filing Activity (PR Newswire)
May-20-24 03:00AM	Clarivate Launches AI-Enhanced Solution to Accelerate Trademark Watching (PR Newswire)
May-16-24 03:00AM	New Clarivate Report Reveals that the U.S., Germany and Mainland China have the most Non-Practicing Entity Litigation (PR Newswire)
May-15-24 03:56PM	Klarman's Baupost Group Buys Stake in SoundHound, Cuts Position in Warner Bros Discovery (Investopedia)
May-09-24 04:49AM	Analyst Report: Clarivate Plc (Morningstar Research)
03:00AM	OMRON Selects IPfolio from Clarivate (PR Newswire)
May-08-24 06:55PM	Analyst Report: Clarivate Plc (Morningstar Research) -11.37%
09:30AM	Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics (Zacks)
07:15AM	Clarivate PLC (CLVT) Q1 Earnings Meet Estimates (Zacks)
06:39AM	Clarivate Posts Loss In Q1; Reaffirms FY24 Outlook (RTT News)
06:00AM	Clarivate Reports First Quarter 2024 Results (PR Newswire)
May-07-24 03:00AM	Clarivate Introduces Epidemiology Intelligence for Precision Patient Population Analysis (PR Newswire)
May-02-24 03:00AM	Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success (PR Newswire)
May-01-24 04:05PM	Clarivate Declares Dividend on Mandatory Convertible Preferred Shares (PR Newswire)
12:41PM	Koninklijke Philips N.V. (NYSE:PHG) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:01AM	Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-30-24 03:00AM	BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report (PR Newswire)
Apr-24-24 03:00AM	Clarivate joins United Nations SDG Publishers Compact (PR Newswire)
Apr-23-24 07:00AM	Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets (PR Newswire)
Apr-17-24 04:00AM	Clarivate Launches LatAm Market Tracking Solution in Partnership with Global Healthcare Intelligence Enabling Real-Time Tracking of Medical Device Markets (PR Newswire)
04:00AM	Clarivate Launches LatAm Market Tracking Solution in Partnership with Global Health Intelligence Enabling Real-Time Tracking of Medical Device Markets (PR Newswire)
Apr-15-24 12:10PM	Will Clarivate (CLVT) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:00AM	Clarivate to Report First Quarter 2024 Results on May 8, 2024 (PR Newswire)
Apr-01-24 09:00AM	Clarivate Leadership Presents at Recent Investor Conferences (PR Newswire)
Mar-28-24 03:22PM	13 High Growth Value Stocks to Invest in According to Seth Klarman (Insider Monkey)
Mar-21-24 04:00AM	Clarivate Acquires AI Start Up to Accelerate Strategy and Business Development Success for Life Sciences & Healthcare Clients (PR Newswire)
Mar-20-24 08:00AM	New Webinar: Clarivate in the Age of AI - Driving Innovation in Intellectual Property Management and Decision Making (PR Newswire)
Mar-19-24 10:07PM	Samsung ranks top Global Innovator while Huawei gets 7th spot (DigiTimes)
Mar-13-24 08:00AM	New Webinar: Clarivate in the Age of AI - Empowering Our Life Sciences & Healthcare Customers to Create a Healthier Tomorrow (PR Newswire)
Mar-12-24 05:26AM	Analyst Report: Clarivate Plc (Morningstar Research)
Mar-08-24 01:04PM	Red Violet, Inc. (NASDAQ:RDVT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 08:00AM	Clarivate to Present at the BofA Securities 2024 Information & Business Services Conference on March 14 (PR Newswire)
Mar-06-24 08:00AM	New Webinar: Clarivate in the Age of AI - Innovation Rooted in Academia (PR Newswire)
Mar-05-24 10:57AM	Clarivate Plc (NYSE:CLVT) Q4 2023 Earnings Call Transcript (Insider Monkey)
03:00AM	Clarivate Reveals Top 100 Global Innovators 2024 (PR Newswire)
Mar-04-24 08:30AM	Clarivate and Exor sign agreement (GlobeNewswire)
08:30AM	Clarivate and Exor Sign Agreement Under Which Suzanne Heywood Will Be Nominated to Stand for Election to the Company's Board of Directors (PR Newswire)
Mar-03-24 11:33PM	12 Best Single Digit Stocks To Invest In (Insider Monkey)
Feb-27-24 09:30AM	Clarivate PLC (CLVT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -17.45%
06:00AM	Clarivate Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-23-24 03:00AM	Clarivate Recognized in the WTR 1000 2024 for Trademark Business (PR Newswire)
Feb-22-24 09:15AM	Countdown to Clarivate PLC (CLVT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-20-24 03:00AM	Clarivate Launches New Center for Intellectual Property and Innovation Research (PR Newswire)
Feb-12-24 03:00AM	Clarivate Partners with the Financial Times to Power its Business School Rankings (PR Newswire)
Feb-01-24 07:00AM	Clarivate Completes Refinancing of Term Loan and Revolver Extension (PR Newswire)
Jan-29-24 03:00AM	Clarivate Launches Web of Science Grants Index to Help Researchers Optimize Funding Strategies (PR Newswire)
Jan-24-24 07:00AM	Clarivate to Report Fourth Quarter and Full Year 2023 Results on February 27, 2024 (PR Newswire)
Jan-22-24 07:00AM	Clarivate Announces Commencement of Term Loan Refinancing Transaction (PR Newswire)
Jan-08-24 03:00AM	Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report (PR Newswire) +6.00%
Dec-19-23 02:00AM	Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm (PR Newswire) +5.31%
Dec-05-23 02:00AM	Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development (PR Newswire)
Nov-15-23 03:00AM	Clarivate Reveals World's Influential Researchers in Highly Cited Researchers 2023 List (PR Newswire)
Nov-08-23 05:12PM	Clarivate Plc (NYSE:CLVT) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.67%
04:15PM	Clarivate to Present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023 (PR Newswire)
Nov-07-23 06:00AM	Clarivate Reports Third Quarter 2023 Results (PR Newswire)
Oct-31-23 03:00AM	Clarivate Report Reveals China Challenging U.S. Research Dominance, Signaling Future Research Ambitions (PR Newswire)
Oct-26-23 03:00AM	Clarivate Partners with EveryLibrary to Support and Nurture Libraries in the U.S. (PR Newswire)
Oct-24-23 03:00AM	BioWorld by Clarivate Examines Impact of Emerging Medicines on Obesity (PR Newswire)
Oct-23-23 12:10PM	Will Clarivate PLC (CLVT) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-18-23 03:00AM	Clarivate Renews Partnership with The Federal Library and Information Network (PR Newswire)
Oct-16-23 09:00AM	Clarivate to Report Third Quarter 2023 Results on November 7, 2023 (PR Newswire) +6.06%
Oct-12-23 03:00AM	Clarivate Report Finds Significant Adoption of AI in IP (PR Newswire)

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAR VEINSTEIN	Officer	Sep 19 '24	Proposed Sale	7.00	120,000	840,000		Sep 19 04:01 PM
SAHA SAURABH	Director	Aug 30 '24	Sale	6.75	17,646	119,110	23,741	Sep 04 04:51 PM
SAHA SAURABH	Director	Aug 30 '24	Proposed Sale	6.75	17,646	119,110		Aug 30 05:05 PM
Snyder Andrew Miles	Director	Aug 09 '24	Buy	5.67	262,000	1,485,540	550,334	Aug 12 04:30 PM
Snyder Andrew Miles	Director	Aug 08 '24	Buy	5.49	28,938	158,870	288,334	Aug 12 04:30 PM

CNTA

Centessa Pharmaceuticals plc ADR

CLVT

Clarivate Plc

Upgrade your FINVIZ experience